Actively Recruiting
Phase II Study of F182112 with Different Treatment Plans in Patients with Relapsed or Refractory Multiple Myeloma
Led by Shandong New Time Pharmaceutical Co., LTD · Updated on 2025-12-31
90
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of F182112 combined with different administration regimens in patients who have relapsed or refractory multiple myeloma. This is a Phase II, single-arm, open-label study conducted at multiple centers, aiming to understand how well this treatment works and its safety profile in this patient group. The study plans to enroll about 90 patients and will test F182112 combined with varying administration schedules. The treatments include combinations such as F182112 plus P and F182112 plus CD38. Participants will receive these study drugs according to different regimens designed to assess their effects. During the study, researchers will monitor participants for up to two years, measuring outcomes like the objective response rate, progression-free survival, overall survival, duration of response, and minimal residual disease status. Safety will be tracked by recording adverse events and serious adverse events. Participants will undergo regular assessments and laboratory tests to evaluate treatment impact and safety throughout the study period.
CONDITIONS
Brief Title
A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Research Team
L
Lu gui Qiu Doctor
S
Shaohong Yin
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here